Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 1295Pancreatic Neoplasms 819Carcinoma, Hepatocellular 782Stomach Neoplasms 754Rectal Neoplasms 565Esophageal Neoplasms 452Colonic Neoplasms 414Esophageal Squamous Cell Carcinoma 277Neoplasm Metastasis 263Cholangiocarcinoma 251Liver Neoplasms 219Neoplasms 200Biliary Tract Neoplasms 179Adenocarcinoma Of Esophagus 139Gastrointestinal Stromal Tumors 108Gallbladder Neoplasms 96Adenocarcinoma 94Breast Neoplasms 91Gastrointestinal Neoplasms 89Carcinoma, Non-Small-Cell Lung 87Bile Duct Neoplasms 69Sarcoma 67Lung Neoplasms 64Ovarian Neoplasms 60Anus Neoplasms 59Melanoma 54Uterine Cervical Neoplasms 52Carcinoma 48Digestive System Neoplasms 45Prostatic Neoplasms 40

Interventions

Nivolumab 1((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Gastroesophageal Adenocarcinoma × Gastrointestinal × Clear all
NCT04021108 2025-06-24

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Weill Medical College of Cornell University

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT00073502 2006-02-22

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

OSI Pharmaceuticals

Phase 2 Completed
43 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡